Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection

Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection

Abstract Background and Aim Immune checkpoint inhibitors (ICIs) can cause immune‐related adverse events in the liver. The risk of exacerbating liver injury is of concern in patients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), as immunotherapy can damage liver function because o...

Full description

Bibliographic Details
Main Authors: Tasuku Nakabori, Yutaro Abe, Sena Higashi, Takeru Hirao, Yasuharu Kawamoto, Shingo Maeda, Kazuma Daiku, Makiko Urabe, Yugo Kai, Ryoji Takada, Takuo Yamai, Kenji Ikezawa, Hiroyuki Uehara, Kazuyoshi Ohkawa
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:JGH Open
Subjects:
hepatitis B virus
hepatitis C virus
immunotherapy
liver injury
Online Access:https://doi.org/10.1002/jgh3.12737

Internet

https://doi.org/10.1002/jgh3.12737

Similar Items